A Phase II Study of Anti-PD-1 Antibody (MK-3475) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Other Low Grade B Cell Non-Hodgkin Lymphoma (NHL)

Trial Profile

A Phase II Study of Anti-PD-1 Antibody (MK-3475) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Other Low Grade B Cell Non-Hodgkin Lymphoma (NHL)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Ibrutinib; Idelalisib
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 19 Apr 2017 Results (n=25, data cut off: 30 June, 2016) from chort A of the study (patients with relapsed or progressive chronic lymphocytic leukemia and chronic lymphocytic leukemia with Richter's transformation), published in the Blood.
    • 22 Dec 2016 Planned number of patients changed from 60 to 68.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top